Literature DB >> 9815646

Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?

C Dosquet1, M C Coudert, E Lepage, J Cabane, F Richard.   

Abstract

Angiogenesis has an important role in the progression of solid tumors. Therefore, we measured the blood levels (ELISA) of angiogenic factors [basic fibroblast growth factor (bFGF), hepatocyte growth factor/scatter factor, and vascular endothelial growth factor (VEGF)] and soluble adhesion molecules [E-selectin, intercellular adhesion molecule (ICAM-1), platelet endothelial cell adhesion molecule-1, and vascular cell adhesion molecule-1] in 76 consecutive patients with untreated renal cell carcinoma and 41 healthy controls to evaluate their prognostic value. The serum levels of bFGF, hepatocyte growth factor, and VEGF were significantly higher in patients with renal cancer than they were in healthy subjects. bFGF and VEGF values were significantly higher in patients with disseminated cancer (N+ and/or M+) than they were in those with undisseminated (M-N-) cancer: median = 27 pg/ml, range = 5-118, n = 15 versus median = 8 pg/ml, range = 1-149, n = 61 (P = 10(-4)) for bFGF; and median = 883 pg/ml, range = 200-2317, n = 15 versus median = 278 pg/ml, range = 0-1704, n = 61 (P = 0.006) for VEGF. The blood levels of ICAM-1 and vascular cell adhesion molecule-1 were significantly higher, and the levels of E-selectin and platelet endothelial cell adhesion molecule-1 were significantly lower in patients with renal cancer than they were in controls. Plasma ICAM-1 was higher in metastatic patients (M+) than they were in nonmetastatic (M-) patients: median = 687 ng/ml, range = 294-1091, n = 12 versus median = 408 ng/ml, range = 217-1375, n = 64 (P = 10(-4)). ICAM-1 and bFGF blood values were correlated with the size of the primary tumor. The interleukin 6 and tumor necrosis factor-alpha (TNF-alpha) values of these patients have been previously published and are included in the survival analysis. Univariate analysis showed that bFGF, ICAM-1, interleukin 6, and TNF-alpha, before treatment, were prognostic factors. In multivariate analysis for proportional hazard regression, only TNF-alpha was an independent prognostic indicator, with a normal plasma TNF-alpha being highly predictive for a good prognosis in patients with untreated renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815646

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

1.  Renal cell carcinoma metastasis to the ciliary body responds to proton beam radiotherapy: a case report.

Authors:  Tarek Alasil; Bahram Khazai; Lilia Loredo; Michael E Rauser
Journal:  J Med Case Rep       Date:  2011-08-03

2.  Serum levels of angiogenic factors and their prognostic relevance in bladder cancer.

Authors:  Tibor Szarvas; Tobias Jäger; Falk Droste; Markus Becker; Ilona Kovalszky; Imre Romics; Süleyman Ergün; Herbert Rübben
Journal:  Pathol Oncol Res       Date:  2008-09-20       Impact factor: 3.201

3.  Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.

Authors:  M Horstmann; A S Merseburger; E von der Heyde; J Serth; G Wegener; M Mengel; G Feil; J Hennenlotter; U Nagele; A Anastasiadis; C Bokemeyer; A Stenzl; M Kuczyk
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

Review 4.  The role of angiogenesis in prostate and other urologic cancers: a review.

Authors:  J I Izawa; C P Dinney
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

5.  Serum concentrations of TNF α and its soluble receptors in patients with adrenal tumors treated by surgery.

Authors:  Jan Komorowski; Jolanta Jurczynska; Tomasz Stepien; Krzysztof Kolomecki; Krzysztof Kuzdak; Henryk Stepien
Journal:  Int J Mol Sci       Date:  2010-05-26       Impact factor: 5.923

6.  Does CD34 Staining Reflect the Angiogenic Process in the Bone Marrow? An Analysis of a Series of Chronic Myeloid Leukemia Patients.

Authors:  Krishnan Kulumani Mahadevan; Debdatta Basu; Swarup Kumar
Journal:  J Clin Diagn Res       Date:  2014-05-15

Review 7.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

Review 8.  Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors.

Authors:  Vitaly Margulis; Christopher G Wood; Eric Jonasch; Surena F Matin
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

Review 9.  A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?

Authors:  E Hormbrey; P Gillespie; K Turner; C Han; A Roberts; D McGrouther; A L Harris
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Darren R Feldman; Michael S Baum; Michelle S Ginsberg; Hani Hassoun; Carlos D Flombaum; Susanne Velasco; Patricia Fischer; Ellen Ronnen; Nicole Ishill; Sujata Patil; Robert J Motzer
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.